Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitors among patients with acute myocardial infarction (AMI) based on real-world experience.

Methods And Results: Data were collected from the Biobank of the First Affiliated Hospital of Xi'an Jiaotong University between January 2016 and December 2020. A total of 7556 AMI patients were screened for eligibility. Propensity Score Match (PSM) was employed, and covariates were age, sex, admission blood pressure and lipid profiles. Eligible participants were (1) propensity-matched 1:2:2 of statin plus evolocumab (dual therapy) vs. statin vs. statin plus ezetimibe. Ninety-five statin plus evolocumab users achieved significantly decreased low density lipoprotein (LDL) levels (0.92 ± 0.62 mmol/L in the 1st month and 1.17 ± 0.73 in the 3rd month) and a promising attainment rate of LDL (79.5% in the 1st month and 80.0% in the 3rd month) compared to the other two groups. (2) Propensity-matched 1:2:2 of statin plus ezetimibe evolocumab (triple therapy) vs. statin vs. statin plus ezetimibe. Similarly, 75 triple medication users achieved significantly decreased LDL levels and a promising attainment rate of LDL compared to the other two groups. In-hospital mortality and readmission rates within 3 months were then analyzed, and a decreased readmission rate was observed with PCSK9i therapy.

Conclusions: Based on the present single-center real-world PSM-adjusted study, PCSK9i has been effective in short-term lipid control among AMI patients. The long-term effectiveness for reducing major cardiovascular events among AMI patients based on real-world experience remains to be explored.

Trial Registration: The study was registered at ClinicalTrials.gov, ClinicalTrials.gov ID: NCT05184530.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590135PMC
http://dx.doi.org/10.1186/s12944-022-01724-9DOI Listing

Publication Analysis

Top Keywords

ami patients
12
statin ezetimibe
12
in-hospital initiation
8
initiation pcsk9
8
short-term lipid
8
lipid control
8
patients acute
8
acute myocardial
8
myocardial infarction
8
pcsk9 inhibitors
8

Similar Publications

ECLS-SHOCK and DanGer Shock: Implications for optimal temporary mechanical circulatory support use for cardiogenic shock due to acute myocardial infarction.

Can J Cardiol

January 2025

University of Montreal Hospital Center (CHUM) Cardiovascular Center & Research Center (CRCHUM), University of Montreal, Montreal, Quebec, Canada. Electronic address:

Despite concerted efforts to rapidly identify patients with cardiogenic shock complicating acute myocardial infarction (AMI-CS) and provide timely revascularization, early mortality remains stubbornly high. While artificially augmenting systemic flow through the use of temporary mechanical circulatory support (tMCS) devices would be expected to reduce the rate of progression to multi-organ dysfunction and thereby enhance survival, reliable evidence for benefit has remained elusive with lingering questions regarding the appropriate selection of both patients and devices, as well as the timing of device implantation relative to other critical interventions. Further complicating matters are the resource-intensive multidisciplinary systems of care that must be brought to bear in this complex patient population.

View Article and Find Full Text PDF

Aims: To identify differences in CT-derived perivascular (PVAT) and epicardial adipose tissue (EAT) characteristics that may indicate inflammatory status differences between post-treatment acute myocardial infarction (AMI) and stable coronary artery disease (CAD) patients.

Methods And Results: A cohort of 205 post-AMI patients (age 59.8±9.

View Article and Find Full Text PDF

Objectives: This study evaluated the effectiveness of "Internet Plus" remote management in enhancing cardiac rehabilitation outcomes for patients with acute myocardial infarction (AMI) following percutaneous coronary intervention (PCI).

Methods: A total of 101 AMI patients post-PCI from Sir Run Run Shaw Hospital were included between December 2021 and November 2022. Patients were retrospectively categorized into two groups based on the type of care they received: the control group receiving standard post-PCI rehabilitation, and the observation group receiving remote management via "Internet Plus" for six months.

View Article and Find Full Text PDF

The purpose of this study is to clarify the influence of acquiring medical record information and laboratory data on the sensitivity of detecting imaging findings among Japanese radiological technologists (RTs). RTs were presented with patient's information in three distinct sequences for detecting imaging findings. True positives (TP) were identified and categorized into three groups: Group 1 (image + chief complaint), Group 2 (image + chief complaint + medical record), and Group 3 (image + chief complaint + medical record + laboratory data).

View Article and Find Full Text PDF

Study on Immune-Related Genes and Clinical Validation of Acute Myocardial Infarction Based on Bioinformatics.

Biochem Genet

January 2025

Department of Emergency, The Wenzhou Third Clinical Institute Affiliated To Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou Maternal and Child Health Care Hospital, Wenzhou, 325000, Zhejiang, China.

Acute myocardial infarction (AMI) is a cardiovascular disease featuring the narrowing and hardening of coronary arteries triggered by a combination of factors, which ultimately leads to the death of heart muscle. We retrieved the GSE109048 and GSE123342 datasets from the Gene Expression Omnibus (GEO) database. After integrating these datasets, we selected 154 module key genes with the help of weighted correlation network analysis (WGCNA).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!